title: [Clinical efficiency of transfusion of pathogen-inactivated platelet concentrates].
abstract: OBJECTIVE
  To evaluate the effect of pathogen-inactivated platelet concentrates (PIPC) on posttransfusion platelet increments, hemorrhagic syndrome relief, and transfusion intervals.
  
  
  METHODS
  This prospective study included 29 hemoblastosis patients (13 women, 16 men), median age 38 years (20-66 years). Pathogens were inactivated by the photodynamic method using the Intecept system. Each patient received two PC transfusions: one PIPC transfusion and one control one. Posttransfusion platelet increments one hour and one day after PC transfusion, the course of hemorrhagic syndrome, and the time to next platelet transfusion were analyzed.
  
  
  RESULTS
  Pathogen inactivation with amotosalen and ultraviolet irradiation reduced posttransfusion platelet increments in recipients by 24% after one hour and by 29% after one day after PIPC transfusion versus control ones.
  
  
  CONCLUSIONS
  The clinical efficiency of transfusions of amotosalen-induced PIPC was comparable with that of untreated platelet concentrates. Despite a reduction in post-transfusion platelet increment with the use of PIPC, this caused no significant increase in the frequency of transfusions.
authors.forename: I M
authors.initials: IM
authors.lastname: Nakastoev
authors.forename: A E
authors.initials: AE
authors.lastname: Grachev
authors.forename: É G
authors.initials: ÉG
authors.lastname: Gemdzhian
authors.forename: N N
authors.initials: NN
authors.lastname: Tsyba
authors.forename: V V
authors.initials: VV
authors.lastname: Zhuravlev
authors.forename: A V
authors.initials: AV
authors.lastname: Krechetova
authors.forename: I S
authors.initials: IS
authors.lastname: Kastrikina
authors.forename: E A
authors.initials: EA
authors.lastname: Vatagina
authors.forename: V V
authors.initials: VV
authors.lastname: Ryzhko
authors.forename: V M
authors.initials: VM
authors.lastname: Gorodetskiĭ
mesh_terms: D000328:Adult; D005260:Female; D011564:Furocoumarins / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy / Q000295:instrumentation / Q000379:methods*; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D017713:Platelet Transfusion / Q000295:instrumentation / Q000379:methods*; D011446:Prospective Studies; D013921:Thrombocytopenia / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D011564:Furocoumarins; D017319:Photosensitizing Agents; C118577:amotosalen